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Reactive oxygen and nitrogen species (e.g. H2O2, nitric oxide) confer redox regulation of essential cellular
signaling pathways such as cell differentiation, proliferation, migration and apoptosis. In addition,
classical regulation of gene expression or activity, including gene transcription to RNA followed by
translation to the protein level, by transcription factors (e.g. NF-κB, HIF-1α) and mRNA binding proteins
(e.g. GAPDH, HuR) is subject to redox regulation. This review will give an update of recent discoveries in
this ﬁeld, and speciﬁcally highlight the impact of reactive oxygen and nitrogen species on DNA repair
systems that contribute to genomic stability. Emphasis will be placed on the emerging role of redox
mechanisms regulating epigenetic pathways (e.g. miRNA, DNA methylation and histone modiﬁcations).
By providing clinical correlations we discuss how oxidative stress can impact on gene regulation/activity
and vise versa, how epigenetic processes, other gene regulatory mechanisms and DNA repair can in-
ﬂuence the cellular redox state and contribute or prevent development or progression of disease.
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The ability of every living organism to leave a progeny is en-
coded by its genome, which is a long DNA chain that contains all
information about the particular organism. Genomes of living or-
ganisms can contain as few as 500 genes (e.g. mycoplasma) and as
many as 20,000–25,000 for humans. Considering how valuable the
integrity of a DNA molecule is, cells developed several protection
systems. First, DNA is contained inside the nucleus, which is sur-
rounded by a selectively permeable membrane. Secondly, DNA is
also localized to the mitochondria, which can either be considered
as a preservation strategy for the cell or a compartmentalization
approach enabling better functional division between DNA
molecules.
DNA located in the nucleus predominantly encodes for RNA
molecules that later on can be translated to proteins. This means
that every piece of information concerning a particular organism is
encoded by nuclear DNA, starting from cell division parameters
and ﬁnishing with information regarding programmed cell death.
Information from DNA is processed via transcription mechanisms,
leading to formation of another nucleic acid chain, namely RNA.
Depending on the type of RNA molecule, translation to amino acid
sequences, the building blocks for proteins, or other functional
roles may occur. DNA located in mitochondria encodes all in-
formation necessary for its robust activity. In particular, mtDNA is
responsible for storing, maintaining and successful implementa-
tion of information regarding among others, main components of
mitochondrial electron transport chain (ETC) including cyto-
chrome b, NADH dehydrogenase subunits, cytochrome oxidase
subunits. In addition to direct transcriptional effects mediated by
transcription factor binding to DNA epigenetic marks due to che-
mical modiﬁcation of cytosine residues of DNA (DNA methylation)
and histone proteins associated with DNA (histone modiﬁcations)
can modulate gene activity and expression as well as chromatin.
Even though cells developed strategies to preserve the integrity
of DNA, multiple factors can alter the structure of DNA [1], among
which are UV irradiation [2], reactive oxygen and nitrogen species
[3], or extrinsic chemical compounds [4]. On average, the DNA of a
mammalian cell receives the following assaults per day: 200 cy-
tosine deaminations, 3000 guanine methylations, 10,000 sponta-
neous depurinations, 10,000–100,000 oxidative lesions, 10,000
single-strand breaks, and 10–50 double-strand breaks [3,5–7].
Every type of DNA damage is source speciﬁc. For example, UV light
is mostly known for strand breaks and/or DNA–DNA cross-links, as
well as DNA–protein cross-link formation [8]. Reactive oxygen and
nitrogen species predominantly induce speciﬁc base modiﬁcation,
such as 8-oxo-dG, 8-nitro-dG [9], or GC to TA transversions due to
their high reactivity with strong nucleophilic sites on nucleobases
[10]. External chemical compounds can introduce particular che-
mical groups, for example alkylation of DNA by methylnitrosourea
[11] or N-methyl-N′-nitro-N-nitrosoguanidine [12] can cause DNA
cross-links (e.g. mitomycin C, cisplatin) [13,14], or enhance for-
mation of single- and double-strand breaks by sealing DNA-to-
poisomerase complexes [15]. One feature of the mammalian gen-
ome is the fact that every type of DNA aberration has a unique
damage response in form of detection and repair systems. In
conclusion, not only regulation of gene expression by transcription
factors and epigenetic pathways, but also DNA damage/repair
largely contributes to genome stability.This review will outline that redox signaling and oxidative
stress will affect expression, transcription and translation of
genomic information not only by classical and epigenetic regula-
tion of gene expression, but also by inﬂicting direct DNA damage
and regulation of the activity of DNA repair enzymes. In the ﬁrst
section, we provide an overview on the different pathways and
enzymatic systems that contribute to genome stability and read-
out of genomic information. In the second section, we focus on the
impact of redox biology and oxidative stress on these different
pathways. In the third section, we correlate these ﬁndings to the
clinical situation. In the fourth section, we summarize the impact
of redox biology and oxidative stress on genome stability as well as
transcription and translation of genomic information.
DNA repair
Depending on the type of DNA modiﬁcation different repair
mechanisms will be activated in order to remove such damage.
Whenever a toxic modiﬁcation on a speciﬁc nucleobase appears or
leads to formation of abasic sites, base excision repair (BER) is
activated to resolve this problem [16]. Key players of the BER are
DNA glycosylases (uracil-DNA glycosylase (UNG) [17], 8-ox-
oguanine DNA glycosylase (OGG1) [18], nth endonuclease III-like 1
(NTHL1) [19] and nei endonuclease VIII-like 1, 2 or 3 (NEIL1/NEIL2/
NEIL3) [20]), all of which recognize different base modiﬁcations;
DNA endonucleases such as apurinic/apyrimidinic endonuclease 1
(APE1) [21]; DNA polymerases (Polβ) and DNA ligases (Lig1) [22].
Speciﬁcity of this repair pathway is achieved by activity of the
glycosylases that scan DNA molecules by slightly pulling the nu-
cleotide strain. If there is a distortion of the helix, caused by a lack
of hydrogen bonding between damaged Watson–Crick base pairs,
these enzymes will ﬂip this nucleobase out, insert it into the cat-
alytic pocket, consequently cleave the N-glycosidic bond between
the damaged base and the 2′-deoxyribose, and generate an
apurinic- or apyrimidinic-(AP) site. All, AP sites are then processed
by apurinic/apyrimidinic endonuclease 1 (APE-1), leaving clean 3′
and 5′ ends that allow DNA polymerase β (Polβ) and DNA ligase I
(Lig1) to insert and ligate the appropriate base [23].
Nucleotide excision repair (NER) on the other hand, is able to
remove larger and more complex types of damage found on DNA,
like intra-strand and DNA–protein cross-links, and bulky forma-
tions [24]. Xeroderma pigmentosum, complementation group C
(XPC), xeroderma pigmentosum, complementation group G (XPG),
RAD23 homolog B (RAD23B), excision repair cross-complementa-
tion group 6 (ERCC6) and others function as damage identiﬁcation
molecules [25]. If the distortion was recognized during the re-
plication process, the stalling of the replication fork will serve as
an identiﬁcation signal [26]. Upon receiving ﬁrst NER up-regula-
tion signals, the complex consisting of XPA, XPG [27], ERCC1,
ERCC4, ERCC3 and replication protein A (RPA) acts as an ex-
cinuclease making two incisions in the DNA strand on either sides
of the lesion. In a next step polymerases are activated to insert the
correct DNA segment in the missing section and ligases will ﬁnish
the repair process by sealing the strand.
If distinct DNA modiﬁcations are not repaired on time by repair
machineries, they might lead to the formation of mismatches after
incorrectly performed transcription. Unfortunately, such unfavor-
able transcriptional outcome can happen even without DNA da-
mage. Mismatch signals as well as small insertion and deletion
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[28]. Major regulators of the MMR are two enzymatic families,
mutator S (MutS) and mutator L (MutL). MutS recognizes base–
base mismatches and small insertion/deletion loops, while MutL is
able to detect longer loops [29]. After the recognition step, these
enzymes initiate the downstream repair cascade, consisting of
accessory proteins including proliferating cell nuclear antigen
(PCNA), replication factor C (RFC), exonucleases (EXO-1) and DNA
polymerases, thereby introducing correct nucleobases into the
DNA gap. Finalization of the repair process is orchestrated by Lig1,
which joins up ﬂanking ends of the DNA molecule [30].
Double strand breaks are considered to be the most severe type
of DNA damage and if not promptly repaired, might contribute to
programmed cell death. Evolutionary, two repair mechanisms
emerged in order to resolve such pathological state, homologous
recombination (HR) and non-homologous end joining (NHEJ) [31].
Recombination mechanisms have to be initiated by endonucleases
that are able to cleave one of the partner DNA duplexes. This is a
complex process which can be accompanied by the activity of the
DNA helicases. After 3′ ends of the DNA molecule have been
cleared from the residual damaged nucleobase they anneal with
the homologous regions in another DNA duplex. In order to allow
this process the homologous duplex is extended to provide extra
space for the approximation of the strands. The loop, which is
formed as a result of this reaction, is extended by adjuvant repair
enzymes, ﬁlling the gap that was left by the damaged nucleobase.
Finally, this loop gets resolved from this repair stage either with orFig. 1. Summary of major DNA repair mechanisms in the mammalian cells. The genom
intracellular damaging factors by different DNA repair pathways. Depending on the type
mechanism will be activated for removal (BER, NER, mismatch repair, non-homologo
glycosylase (UNG), 8-oxoguanine DNA glycosylase (OGG1), nth endonuclease III-like 1 (N
DNA damage detection complex: xeroderma pigmentosum, complementation group
plementation group 6 (ERCC6). Excision of the effected DNA section is conducted by
plementation group A, G (XPA, XPG), replication protein a (RPA) and excision repair cro
complex: mutator S (MutS) and mutator L (MutL) and by speciﬁc repair machinery:prolif
to Luo et al. [106].without the cross-over of the genetic information, leaving behind
a footprint of the genetic code from the homologous region [32].
When homologous strands are not present for the recombination
pathway, a process called non-homologous end joining (NHEJ) is
activated. It is initiated by Ku70 and Ku80 complexes [33] that
bring the DNA strands together and attract the Mre11–Rad50–
Nbs1 (MRN) complex that ﬁnalizes the approximation process.
Joining of the broken ends is performed by a speciﬁc DNA ligase IV
(LigIV). X-ray repair cross-complementing protein 4 (XRCC4)
supports LigIV in the ligation process [34]. Homologous re-
combination and non-homologous end joining pathways are
highly mutation-prone due to the already missing section of the
DNA molecule and potential loss of certain open reading frames,
which will later cause functional abnormalities. The major DNA
repair pathways are summarized in Fig. 1.
Classical gene regulation
A DNA molecule is a carrier of information, covering most as-
pects of the organism's development and sustainability (role of
miRNA and other noncoding RNAs will be discussed below). Al-
though DNA contains all these data, it has tight regulation over the
information release through the activation or repression of genes.
Such regulation happens through many distinct pathways, which
generally can be summarized into two sub-classes: classical gene
regulation, which takes place through the activity of transcription
factors and novel gene regulation through epigenetic regulators.e of the mammalian cell is well protected from the plethora of extracellular and
of DNA modiﬁcation that has been introduced to the nucleic acid, appropriate repair
us end joining (NHEJ)). Major DNA glycosylases in BER pathway are: uracil-DNA
THL1), nei endonuclease VIII-like 1–3 (NEIL1-3). Speciﬁcity of NER is achieved by its
C, G (XPC, XPG), RAD23 homolog B (RAD23B) and excision repair cross-com-
members of the excinuclease excision complex: xeroderma pigmentosum, com-
ss complementation group 1, 3, 4 (ERCC1,3,4). MMR is directed by the recognition
eration cell nuclear antigen (PCNA) and replication factor c (RFC). Concept according
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Among some of the most well-studied, redox-sensitive transcrip-
tion factors are NF-κB [36], Nrf2 [37], estrogen receptor [38], hy-
poxia inducible factor-1 (HIF-1) [39], and transcription cofactors
RNA helicases [40]. The estrogen receptor (ER) is a ligand-depen-
dent transcription factor. It exhibits its effect on DNA through
binding to discriminatory DNA motifs known as the estrogen re-
sponse elements (EREs), half-EREs, or through protein–protein
interactions with other transcription factors including speciﬁcity
protein 1 (SP1), activator protein 1 (AP1), paired-like home-
odomain 1 (Pitx1), and Runt-related transcription factor 1 (Runx1).
ER association with DNA requires recruitment of pioneering fac-
tors, in particular forkhead box protein A1 (FOXA1), which binds to
ER responsive sites before cell activation takes place in order to
create favorable epigenetic conditions for ER binding and tran-
scriptional activation [41].
NF-κB signaling is involved in a plethora of cellular pathways
including inﬂammatory responses, cell cycle regulation, and im-
munity development [42]. The NF-κB transcription factor family
consists of ﬁve proteins, p65, RelB, cRel, p105/p50 and p100/p52.
These proteins can form different aggregates and are able to in-
duce or repress gene expression of speciﬁc target genes. As NF-κB
is involved in such complex and multi-dimensional signaling
networks, its activation is triggered by different pathways, the
canonical (classical) branch and the non-canonical (alternative)
branch. They differ in the initial receptor activation and the sub-
sequent signaling cascades, ultimately leading to NF-κB activation.
Besides the canonical and the alternative pathway, additional
pathways of NF-κB activation exist, sometimes termed atypical
activation pathways [43,44]. NF-κB activation is also highly redox-
regulated and thiol oxidation via activator protein 1 (AP-1),
thioredoxin and IκB degradation activates NF-κB [45–47].
The nuclear factor erythroid related factor 2 (Nrf2), is a member
of the cap ‘n’ collar family of transcription factors [48]. Under
physiologic stationary conditions, Nrf2 is constantly degraded by
the proteasome. This pathway is enabled by direct activity of
kelch-like ECH associated protein 1 (Keap1). Keap1 couples with
Cullin3 ubiquitin E3 ligase and afterwards poly-ubiquitinates Nrf2,
tagging it for proteasomal degradation. The major function of Nrf2
is the maintenance of redox homeostasis. Upon stimulation with
various exogenous and endogenous factors, and in particular by
oxidative stress, cytosolic Nrf2 will not be ubiquitinated and de-
graded, but translocates into the nucleus, where it binds to the
antioxidant responsive elements (ARE) located in promoter re-
gions of genes, and activates the transcription of several anti-
oxidant genes including nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase quinone oxidoreductase 1 (NQO1),
heme oxygenase-1 (HO-1), glutathione S-transferase, superoxide
dismutase (SOD2), catalase, and γ-glutamate cysteine ligase (GCL).
Up-regulation of all these protective enzymes enables a strong
response to oxidative stress [49].
Hypoxia-inducible transcription factors of the HIF family are
major regulators of the cellular adaptation to hypoxia, but are also
sensitive to reactive oxygen species (ROS) and nitric oxide (NO)
[39]. The α-subunit of this heterodimer is hydroxylated at speciﬁc
prolines by prolyl hydroxylases (PHD) under normoxic conditions.
This allows binding of the ubiquitin E3 ligase von Hippel Lindau
protein (pVHL) and subsequent degradation by the proteasome.
PHDs are non heme Fe(II)- and 2-oxoglutarate-dependent dioxy-
genases, which require ascorbate as cofactor [50]. Under hypoxia
PHD activity is decreased, thus preventing degradation of the HIF-
1α subunits and subsequent transcriptional regulation of hundreds
of target genes. While ROS sensitivity of HIF-1α is partially medi-
ated by its transcriptional regulator NF-κB, ROS also can act via
modulating PHD activity [51–53] either by interaction of ROS with
iron by Fenton chemistry or by direct oxidation of the iron centeritself. Recently, it has been shown that FIH, an asparagine hydro-
xylase, which regulates transcriptional activity of HIF-1α, is highly
sensitive to peroxides [54]. Additionally, NO was reported to in-
duce HIF-1α under normoxic conditions. While S-nitros(yl)ation of
HIF-1α was demonstrated in vitro, the biological signiﬁcance and
any role in HIF-1α stability regulation by nitrous(yl)ation awaits
clariﬁcation [55]. Moreover, Chowdhury and colleagues proposed
that the catalytic domain of PHD2 can react in vitro with NO at
the active site Fe(II) and at cysteine residues [56] (note by the
authors: NO is unlikely to react with thiols directly but requires
either so-called “oxidative nitrosation” conditions, e.g. by the
presence of ROS or high NO concentration plus oxygen tension, or
preformation of nitrosating species such as N2O3 or nitroso-thiols
with trans-nitrosating reactivity [57]).
Finally, the successful “activation” of a speciﬁc gene and its
translation to a protein is also determined by post-transcriptional
regulation of mRNA stability depending on sequences found in the
3′-untranslated (3′-UTR) region of the mRNA [58]. For most spe-
cies AU-rich elements (AREs) are highly conserved in the 3′-UTR
region, representing binding sites for proteins like HuR or KSRP,
which stabilize or destabilize mRNAs. According to observations
by Kleinert and colleagues this mechanism contributes to the in-
duction of HO-1 expression by the nitrovasodilator pentaerithrityl
tetranitrate [58].
Epigenetic changes by direct DNA or histone modiﬁcations
Epigenetic regulators are able to pose a speciﬁc effect on the
chromatin structure by reversible chemical modiﬁcation of the
DNA molecule itself or on co-localized histone proteins. One of the
most studied epigenetic marks is DNA methylation. This mod-
iﬁcation is considered gene repressive, preventing the transcrip-
tion process [59]. The most common sites at which DNA methy-
lation is detected, are CpG islands, which are cytosine–guanine
pairs that are present in particular high abundancy at certain
sections of the DNA [60]. The 5th position on cytosine is the pre-
ferred methylation point [61]. A general overview of most com-
mon DNA modiﬁcations is shown in Fig. 2. Differential methylation
states of DNA have been implicated in the maintenance of the
normal physiology like genomic imprinting, inactivation of the X
chromosome, as well as in pathological states like Angelman
syndrome, Beckwith–Wiedemann syndrome and several types of
cancer [62]. On the other hand, emerging data suggest that DNA
methylation should not be plainly considered as a silencing mark:
Depending on the location in the chromatin environment and the
presence of transcription markers that are associated with this
particular gene cluster, methylation can be either a transcription
activating or repressing mark [63].
Another class of epigenetically regulated molecules are his-
tones. These protein conglomerates are tightly associated with
DNA to form the chromatin structure [64]. Among the most typical
epigenetic marks observed on histones are methylation, acetyla-
tion, ubiquitination, sumoylation and ADP-ribosylation [65]. Pre-
dominantly, these modiﬁcations are introduced on lysine and/or
arginine residues of the N-terminal tails due to their steric ac-
cessibility. Every moiety found on histones has a speciﬁc effect on
the chromatin state and consequently downstream on gene ex-
pression levels. Histone acetylation is attributed to the formation
of euchromatin, a more relaxed chromosomal state, which leads to
transcriptional activity and inhibition of DNA methylation [66].
Histone deacetylation on the other hand will result in a condensed
chromatin state and is associated with transcriptional repression
[67]. Histone methylation often serves as a read out mark for DNA
binding proteins or transcription factors, which in turn can acti-
vate versatile signaling cascades [68,69]. A summary of currently
known histone modiﬁcations is shown in Fig. 2. Many studies in
Fig. 2. Overview of the epigenetic processes taking place in the cell. Histone structures are shown as H1, H2A, H2B, H3 and H4 according to the accepted terminology. Major
modiﬁcations that are found on their lysine and arginine tails are methylation, acetylation, ubiquitination, phosphorylation and sumoylation. The DNA helix is subjected
majorly to two epigenetic changes – methylation and hydroxymethylation of the 5th position of cytosine. Another epigenetic mechanism is the RNA-based pathway. Concept
according to Wang et al. [72].
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marks, although there is increasing evidence that epigenetic al-
terations also contribute to other pathological conditions, includ-
ing cardiovascular diseases [70].
Epigenetic changes by non-coding RNA
DNA methylation and histone modiﬁcations alone cannot or-
chestrate the whole plethora of epigenetic changes that have been
detected. Such observations led to an extensive search for otherFig. 3. Schematic representation of the miRNA maturation process. As a result of the
microRNA is formed and is exported to the cytoplasm for further processing. Dicer and
mature miRNA which will be catalytically active. Concept according to Wang et al. [72]players in the intricate epigenetic cascades. Current information
shows that only 2% of the human genome is being transcribed into
protein-encoding RNA, while the rest of the genetic material, ap-
proximately 70–90%, is transcribed into non-coding RNAs
(ncRNAs) [71]. There is high abundancy and variability among
these molecules including ribosomal RNAs (rRNAs), microRNAs
(miRNAs) and long non-coding RNAs (lncRNAs). miRNAs are short
RNA molecules, commonly with 22 nucleotides [72]. The matura-
tion process of miRNA is very similar to mRNA, being governed by
Drosha–DGCR8 complex [73]. During extraction from the nucleus,successful transcription and activity of the Drosha complex in the nucleus pre-
RNA-induced silencing complex (RISC) complexes are ﬁnalizing formation of the
.
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cytoplasm and later assembly of the miRNA–RNA-induced silen-
cing complex (RISC) duplex leads to the formation of the active
miRNA molecule [73]. The details of the miRNA maturation pro-
cess are shown in Fig. 3. miRNA have been described to play a role
in repression of target mRNA translation, de-adenylation of mRNA
tails, as well as in regulation through the recruitment of speciﬁc
proteins to the nucleus. lncRNAs are a broad family of molecules,
each having structural and functional distinctiveness. Among
functions attributed to lncRNAs are involvement in embryonic
pluripotency, cell differentiation and development, and chromo-
somal stability [74]. Additionally, lncRNA have been implicated in
several pathological conditions such as Russel–Silver and Prader–
Willi syndrome, cardiac diseases and neurodegenerative disorders
[75].Impact of redox signaling and oxidative stress on gene reg-
ulation and DNA repair
Redox regulation versus oxidative stress
Many diseases and drug-induced complications are associated
or even based on an imbalance between the formation of reactive
oxygen and nitrogen species (ROS and RNS), and antioxidant en-
zymes catalyzing the break-down of harmful oxidants [76,77]. An
imbalance between the oxidant formation and detoxiﬁcation will
ultimately lead to accumulation of oxidative damage in many
biomolecules (e.g. lipid peroxidation with subsequent formation of
reactive aldehydes and ketones, protein carbonylation, nitration
and sulfoxidation, DNA lesions such as 8-oxo-dG) and impaired
redox signaling (e.g. interference with H2O2 signaling that reg-
ulates cell differentiation, proliferation and migration). This con-
dition is termed oxidative stress [78,79]. Many cardiovascular,
neurodegenerative, and inﬂammatory diseases as well as cancer
are associated or even triggered by oxidative stress [80–83]. Oxi-
dative stress is a well-established hallmark of cardiovascular dis-
ease [84] and strong evidence for a causal role of ROS and RNS in
these processes is based on improvement of cardiovascular com-
plications by genetic deletion of enzymes involved in the synthesis
of these reactive species as well as overexpression of antioxidant
enzymes detoxifying these reactive species [76,85]. In accord, in
most animal studies overexpression of reactive oxygen and ni-
trogen species producing enzymes as well as deletion of anti-
oxidant enzymes resulted in aggravation of cardiovascular com-
plications [76,85].
Based on these considerations, the oxidant/antioxidant equili-
brium is an attractive target for therapeutic intervention and large
scale clinical studies have been conducted to prove the efﬁcacy of
antioxidants (namely vitamins) by oral treatment of patients (e.g.
HOPE, HOPE-TOO; for review see [76,86]). It was a great dis-
appointment to realize that these antioxidant trials revealed in
most cases no effects or in some patients even detrimental out-
comes (e.g. for vitamin E) [86–89]. In contrast, a number of small
scale studies using acute, high-dose intravenous infusion of anti-
oxidants demonstrated remarkable beneﬁts in various diseases
(reviewed in [86]). Even more convincing are experimental data
on the effects of antioxidants in several animal disease models
[85]. Potential explanations for this obvious discrepancy could be
that either the achievable dose of oral antioxidant therapy was not
high enough or that systemic therapy with non-speciﬁc anti-
oxidants interferes with redox signaling pathways controlled by
ROS and RNS (reviewed in [76,86]). Antioxidant therapy might be
more successful when using antioxidants with tissue- or cell or-
ganelle-speciﬁcity (e.g. mitochondria-targeted compounds such as
mitoQ) [90], activators of endogenous antioxidant pathways (e.g.Nrf2/HO-1) [91] or source speciﬁc inhibitors (e.g. different Nox
isoforms) [92], thus leaving important cellular redox signaling
mechanisms intact. In the subsequent sections we will discuss the
contribution of redox signaling and oxidative stress to gene reg-
ulation and DNA repair in order to highlight that systemic anti-
oxidant therapy could have signiﬁcant positive or negative impact
on these essential cellular functions.
Redox impact on classical gene regulation
The notion that redox signaling and oxidative stress can change
gene transcription and translation as well as the integrity of the
DNA repair systems is well supported by the literature [93]. Many
transcription factors are regulated in a redox-sensitive fashion
involving zinc-ﬁnger motifs or transition metal centers [94,95]. For
example, the bacterial oxidative stress regulator OxyR is activated
by hydrogen peroxide-induced thiol oxidation or S-nitrosation by
nitric oxide-derived nitrosating species and induces antioxidant
genes [96]. The transcription factor Nrf2 is activated upon thiol
oxidation of its regulator protein kelch-like ECH-associated protein
1 (Keap1) [97] and confers antioxidant protection (e.g. by up-
regulation of HO-1). Thiol oxidation via activator protein 1 (AP-1),
thioredoxin and IκB degradation activates NF-κB [45–47], while
AP-1 is activated upon thiol oxidation via thioredoxin and reg-
ulates antioxidant genes [45,98] (for AP-1 molecular mechanism
see Fig. 4). Further, hydroxylation of HIF-1α by prolyl hydroxylases,
which might be inactivated by oxidation or nitrosylation of the
ferrous iron-containing active site [99], or by the peroxide sensi-
tive asparagine hydroxylase FIH [54], results in its degradation by
the proteasome or in transcriptional inactivation, respectively.
Redox regulation of transcription factors is summarized in Fig. 5.
Likewise, ROS (in most cases hydrogen peroxide) and RNS (e.g.
peroxynitrite via oxidation or nitric oxide via S-nitrosation) can
affect mRNA stability by redox modiﬁcation of proteins that bind
to AU-rich elements (AREs) in their 3′-untranslated (3′-UTR) re-
gion [100]. Examples are (i) glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), which binds to AREs of endothelin-1 mRNA
and decreases its half-life, whereas under oxidative stress condi-
tions binding of GAPDH is inhibited by S-glutathionylation, leading
to increased endothelin-1 protein expression [101]; (ii) ROS and
RNS activate AP-1 leading to decreased expression of the mRNA
binding protein HuR and accordingly to a shorter half-life of the
mRNA of soluble guanylyl cyclase [102]; (iii) nitric oxide and the
nitrovasodilator pentaerithrityl tetranitrate improve HuR binding
to HO-1 mRNA, increasing its half-life and HO-1 protein expres-
sion [58,103]; (iv) mRNA binding proteins such as KSRP and TTP
promote the decay of oxidative stress-regulated genes such as
c-fos, c-jun, inducible nitric oxide synthase (iNOS), GM-CSF, COX-2,
IL-3, TNF-α and IL-2, probably by competing with mRNA stabilizing
proteins such as HuR [100]. At least for TTP, increased expression
levels were reported in oxidative stress conditions [104]. Redox
regulation of mRNA binding proteins is summarized in Fig. 6.
Redox regulation of DNA repair
A wide network of regulatory enzymes tasked with oxidation–
reduction reactions exists in the nucleus. Major players main-
taining the redox balance are glutathione (GSH) and thioredoxin-1
(Trx1), which often switch from cytosolic to nuclear localization
[105]. Recent data indicate that these sulfhydryl biomolecules are
not in a state of the chemical equilibrium, suggesting distinct
targets [105]. Until lately, investigations of thiol/disulﬁde systems
in DNA damage and repair have concentrated on determining their
protective properties against ROS/RNS and only recently the role of
redox signaling and the putative regulation of the DNA repair
machinery through redox reactions has been explored [106].
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Fig. 4. PyMOL representative image of the human isoform of the APE-1 endonuclease and its suggested mechanism of action. The redox N-terminal region of the enzyme is
marked in orange. This section of the molecule is an evolutionary novelty for the human isoform. Redox components of the catalytic pocket, in particular Cys65 and Cys310
are highlighted in red. Based on the current knowledge of APE-1 enzymatic activity, we are suggesting a mechanism that emphasizes the importance of Cys65 for the
process. TF – transcription factor. Concept according to Luo et al. [106]. Protein database ﬁle (1BIX) was used for rendering the structure with PyMOL (Schrödinger, USA).
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chinery by inhibiting a number of important DNA repair enzymes
[9], but also increases the burden of oxidative DNA lesions such as
single strand breaks, 8-nitro-dG and 8-oxo-dG [10].
In the past, nuclear GSH functions were studied in the context
of DNA synthesis, management of the nuclear matrix organization
and preservation of cysteine (Cys) residues on the DNA-binding
motifs of nuclear proteins in a reduced state [107]. Recently
though, there has been a shift in investigating involvement of GSH
in the maintenance of the DNA repair machinery in the functional
state. Major regulators of the DNA repair machinery are glutar-
edoxins (Grxs) [108]. These are thiol-disulﬁde oxidoreductases
that perform GSH/GSSG oxidation–reduction reactions with Cys onFig. 5. ROS effects at the nuclear level. Reactive oxygen species can display their regula
One of the prominent pathways attributed to oxidative stress is thiol oxidation, which is
represent another class of redox-dependent enzymes. For example, epigenetic involvemselected proteins. Grxs are divided into two mechanistic groups,
depending on the structure of their active motif: –Cys–Gly–Phe–
Ser–, which are monothiol Grxs, and –Cys–Pro–Tyr–Cys– that are
dithiol Grxs [109].
Thioredoxins are thiol-disulﬁde oxidoreductases of small mo-
lecular weight (12 kDa), which easily translocate into the nucleus.
This class of enzymes is considered essential for overseeing and
controlling redox signaling [110]. So far, two isoforms of mam-
malian thioredoxins have been detected, Trx1 and Trx2. Both of
them tackle post-effects of oxidative stress in speciﬁc cellular
compartments. Trx2 is predominantly detected in mitochondria,
while Trx1 is found in the cytoplasm and nucleus. Upon detection
of oxidative stress, Trx1 is transported from the cytoplasm to thetory effect on the classical gene regulatory machinery and on epigenetic processes.
involved in OxyR, NF-κB and Keap1 signaling. Oxygen sensing prolyl hydroxylases
ent of ROS has been attributed to oxidative conversion of 5-mC to 5-hmC.
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Fig. 6. ROS impact on mRNA stability at the cytosolic level. Reactive oxygen species are involved in GAPDH signaling by directly altering its structure with the help of GSH or
S-nitrosoglutathione (GSNO), and thus activate translation of endothelin-1 (ET-1) mRNA. AP-1 thiol redox regulation directly affects the gene regulating factor HuR by
stability of its target mRNAs. ROS have been implicated in the regulation of miRNA pathways, altering mRNA stability and their transport inside the cytosol. HRE means
hormone response element.
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GSH, Grx and Trx1 were reported to protect the nucleus from
oxidative DNA damage by regulating induction of DNA repair en-
zymes [112], among other chemical reactions through S-glu-
tathionylation. Trx1 was directly responsible for the reduction of
the major DNA endonuclease APE1 [113]. APE1 has truly unique
functions in the nucleus, as it has both repair and redox regulatory
domains [114]. Redox function of this protein is a new evolu-
tionary addition found only in mammals, while repair function is
conserved through evolution. The endonuclease APE1 is an es-
sential member of nucleotide excision repair, performing cleavage
of the ﬂanking DNA ends to prepare them for polymerase and li-
gase activities. Another redox active, ubiquitously expressed en-
zyme, GAPDH, has been reported to associate directly with APE1
via its active site cysteine 152, thereby reducing APE1 to its
functional state and enabling restoration of its endonuclease ac-
tivity [115]. A completely unexpected facet of APE1 is its redox
activity that affects many major transcription factors such as p53
[116], HIF-1α [117], AP1 [114], NF-κB [118], cAMP response ele-
ment-binding protein (CREB) [119] and many others. This redox
activity of APE1 depends on Cys65, which was conﬁrmed by
multiple amino acid substitution studies [120]. The exact mode of
interaction of this enzyme with such structurally distinct proteins
is still enigmatic. Additional data suggest direct redox regulation of
the DNA repair function of APE1 via oxidation/reduction of cy-
steine residues (e.g. Cys310 adjacent to a crucial His309 in the
active site) [106,121].
One of the initiating enzymes of the non-homologs end joining
(NHEJ) repair process is the Ku family of enzymes. Ku binding to
the ﬂanking ends of the broken DNA enables formation of the
repair complex, consisting of several DNA dependent protein ki-
nases and ligases [122]. Up to now, factors that were contributing
to the enhanced or reduced afﬁliation of Ku proteins to DNA are
still not fully determined, although it was shown that Ku enzymes
bind to DNA in a sequence-independent manner and move along
the DNA molecule in an ATP-independent manner [123]. It became
apparent that the redox state of the enzyme is a fundamentaldriving force for its binding to DNA. Oxidative stress is able to
inhibit Ku’s ability to colocalize with DNA and triggers speciﬁc
conformational changes in the enzyme upon its oxidation that are
increasing its Koff rate [124]. Currently, glutathione is thought to be
the most likely regulator of the Ku enzyme redox state.
O-6-methylguanine-DNA methyltransferase (MGMT) is one of
the most speciﬁc DNA repair enzymes and is recruited to remove
alkyl modiﬁcations from guanine. In addition, this protein is redox
regulated. In particular, MGMT is inhibited by S-nitrosation at the
reactive, essential cysteine that performs the nucleophilic attack at
alkylated nucleobases and confers dealkylation by alkyl transfer,
thereby inactivating MGMT itself (suicide enzymatic reaction)
[125]. It is very likely that MGMT is also inhibited in the setting of
oxidative stress by direct oxidation or by S-glutathionylation.
Redox regulation of epigenetic pathways
There is increasing support for the concept that redox signaling
and oxidative stress can affect the epigenetic regulation of genes
by changes in the function of histones and DNA modifying en-
zymes, thereby altering the phenotype of cells [126]. Likewise,
epigenetic changes may alter the redox environment of a cell.
Accordingly, epigenetic targeting of these different processes may
provide new therapeutic strategies to prevent oxidative stress
disorders including Alzheimer's disease, Parkinson's disease, car-
diovascular disease and cancer [127–129]. Numerous examples of
oxidative stress-associated disease show characteristic patterns of
epigenetic changes. Neprilysin, a neutral endopeptidase (NEP),
which degrades the amyloid beta peptide and thereby prevents its
misfolding and aggregation in brain tissue, was found hy-
permethylated in Alzheimer’s disease. Neprilysin hypermethyla-
tion explained the decreased protein expression levels observed
during the disease [130]. A vital interplay between oxidative stress
and epigenetic changes (e.g. chromatin remodeling) was identiﬁed
in various models of alveolar inﬂammation in general and chronic
lung disease in particular [131,132]. Especially, histone deacety-
lases (e.g. class III HDAC, SIRT1) were identiﬁed as redox-sensitive
Y. Mikhed et al. / Redox Biology 5 (2015) 275–289 283key players in the development and progression of chronic ob-
structive pulmonary disorder (COPD) [133]. Increased ROS and
RNS formation in an inﬂammatory setting will also favor the de-
velopment of lung cancer, most likely involving similar epigenetic
changes [134]. Finally, prominent miRNAs are regulated by oxi-
dative stress [127] and vise versa can regulate antioxidant path-
ways (e.g. Nrf2/HO-1), and may even act in a redox sensitive
manner (“redoximiRs”), allowing adjustment of their action to the
cellular redox state or disease-associated oxidative stress condi-
tion [135]. For example, levels of miR-141, miR-429 and miR-200
family members are increased by ROS, leading to endothelial cell
apoptosis and senescence [136]; miR-141 and miR-200a may
participate in ovarian tumorigenesis via an oxidative stress re-
sponse [137]; the miR-29 family plays a role in lung ﬁbrosis via
regulation of DNA methylation and all of these miRs are regulated
by oxidative stress [138,139]; miR-433 targets gene activation of γ-
glutamyl-cysteine ligase (GCL), the rate-limiting enzyme in the
synthesis of GSH, thus decreases GSH levels, and thereby leads to
changes in cellular redox state and alterations of endothelial cell
function and ﬁbrotic processes [140]. Impact of redox regulation
on miRNAs is summarized in Fig. 6.
Epigenetic changes are also directly linked to ROS. ROS levels,
most likely hydrogen peroxide from NADPH oxidases Duox1/2 and
upon dismutation of Nox2 (CYBB)-derived superoxide can be di-
rectly regulated by epigenetic mechanisms, for example down-
regulated by DNA hypermethylation and histone hypoacetylation
at the genomic level, while ROS generated by these sources can
lead to increased DNA methyltransferase (DNMT) and HDAC ac-
tivity, which in turn may “silence” the DUOX1/2 and CYBB genes in
a feedback fashion [141,142]. Recently, the upregulation of Nox4
by epigenetic mechanisms was reported for cellular senescence in
lung ﬁbroblasts [143]. Likewise, ROS derived from NADPH oxidase
or other sources such as xanthine oxidase, mitochondrial electron
transport chain, uncoupled NO synthase or P450 enzymes can
alter the activity of other target genes [141], for example of the
tumor suppressor E-cadherin. E-cadherin is silenced by DNA hy-
permethylation and histone hypoacetylation by interaction with
the transcription factor SNAIL, DNMT1 and HDAC1 under oxidative
stress conditions, which is a common carcinogenic event [144]. In
another example Nox5-derived ROS were responsible for genetic
silencing of the p16 tumor suppressor [145]. Matrix metallopro-
teinase-1 (MMP-1) expression contributes to the pathogenesis of
numerous degenerative diseases. MMP-1 activity is increased un-
der oxidative stress conditions and further augmented by SOD2
overexpression due to proteasomal degradation of HDAC2 and
accumulation of histone H3 acetylation marks in the MMP-1
promoter [146]. All of these redox regulatory changes were re-
versed by catalase overexpression. SOD2 deﬁciency resulted in
signiﬁcant decrease in global histone epigenetic marks such as
2meH3K4, 3meH3K9, 2meH3K27, 3meH3K27 and AcH3K9 [147].
Interestingly, SOD1 and GPx1 deﬁciency differentially regulate
epigenetic pathways. SOD1 deﬁciency increases histone H3 acet-
ylation and H3K4 methylation in the promoter region of pdx1 and
pdx1 binding to the transcription factor FOXA2 in islet cells,
whereas GPx1 deﬁciency upregulates these parameters. Double
knockout of SOD1 and GPx1 in mice displays the phenotype of
SOD1 deﬁciency [148]. The data suggest opposite roles of super-
oxide and hydrogen peroxide in these epigenetic pathways.
Histone deacetylases (HDACs) represent a group of epigeneti-
cally active enzymes catalyzing the deacetylation of histone lysine
residues [149,150]. An appreciable portion of HDACs are prone to
redox regulation, among them sirtuins [93,133,151,152]. While
most HDACs contain an Zn(II) active site and catalyze the simple
hydrolysis of the amide group, sirtuins link the deacetylation to
NADþ hydrolysis yielding nicotinamide (an inhibitor of sirtuins),
2′-O-acetyl-ADP-ribose and the deacetylated histone as products.This allows speciﬁc regulation of sirtuins in a NADþ/NADH (or free
nicotinamide)-dependent fashion, making them perfect sensors of
the metabolic and energetic state of cells and regulators of a wide
range of cellular processes like transcription, (oxidative) stress
resistance, aging, inﬂammation, apoptosis, metabolic control, but
also circadian clocks and mitochondrial biogenesis. Sirtuin-1, for
example, can be regulated by S-glutathionylation, a redox reg-
ulatory mechanism that largely depends on the cellular redox
state [153]. Glutaredoxin-2 mediated deglutathionylation in-
creased sirtuin-1 activity under oxidative stress conditions [154]
and a triple mutant of sirtuin-1 (with 3 cysteines exchanged by
serines: C61S, C318S, C613S) was resistant to oxidative stress-in-
duced inhibition of the enzyme [155]. In general, sirtuins can be
regulated by toxic aldehydes such as acrolein or 4-hydroxynonenal
(4-HNE) formed under oxidative stress conditions [156–158]. Of
note, ROS increase the levels of 4-HNE and both species are strong
activators of p38 MAPK, which regulates certain lysine acetyl-
transferases (e.g. KAT3A/KAT3B (CBP/p300)) [133,159].
Jumonji C (JmjC) domain-containing histone demethylases
catalyze the demethylation of histone lysine residues in a two-step
mechanism. First, a hydroxylation reaction occurs that converts
the methyl group through Fe(II) and 2-oxoglutarate-dependent
oxidation, followed by spontaneous elimination of formaldehyde
and release of the demethylated lysine [160]. JmjC enzymes belong
to the family of Fe(II)- and 2-oxoglutarate-dependent oxygenases
similar to PHDs. Thus, ascorbate is an essential cofactor for this
class of enzymes to maintain the ferrous (Fe(II)) state required for
enzymatic activity [160,161] (Fig. 5). JmjC enzymes also require
molecular oxygen for their function. However, in hypoxic condi-
tions JmjC is strongly induced by HIF-1α and overall activity of
JmjC is maintained in hypoxia despite the reduced oxygen tension
[162]. The facilitated ferrous state of the JmjC enzyme under hy-
poxic conditions could also contribute to its conserved activity.
Similar considerations with regard to vitamin C and oxygen ten-
sion apply for TET DNA hydroxylases, which catalyze the oxidation
of methyl groups in the 5′-position of cytosine in DNA [160]. Al-
though TET DNA hydroxylases might belong to the DNA repair
machinery, they also directly change the pattern of DNA
methylation.
In summary, both JmjC histone lysine demethylases and TET
DNA hydroxylases confer direct epigenetic changes in histones and
DNA. Both enzymes rely on a ferrous catalytic center that is easily
oxidized to ferric state by superoxide, hydrogen peroxide and
peroxynitrite as well as other ROS. Ascorbate was discussed for
both enzymes as an essential cofactor to keep the ferrous catalytic
center in the reduced state. Since ascorbate levels change with the
cellular redox state this process could represent a redox switch for
enzymatic activity of JmjC histone lysine demethylases and TET
DNA hydroxylases. JmjC domain histone demethylases are not only
regulated by cellular redox state, but can also confer antioxidant
protection as shown for Ndy1 under oxidative stress conditions
and cellular apoptosis [163]. In contrast, the mammalian ﬂavin-
dependent histone lysine-speciﬁc demethylase 1 (LSD1) generates
hydrogen peroxide during its catalytic cycle, which can oxidize
nearby deoxyguanidine (dG) nucleobases, leading to inefﬁcient
gene activation when not immediately coupled with the base ex-
cision repair (BER) enzyme OGG1 that removes the 8-oxo-dG le-
sions [164]. An example is LSD1/BER-dependent estrogen receptor
(ER)-induced activation of the bcl-2 gene, which in the absence of
OGG1 would be suppressed by LSD1-mediated oxidation of the
nearby guanidine bases to 8-oxo-dG during H3K9me2 demethy-
lation [165].
In addition, direct chemical effects of ROS and RNS on nu-
cleotides are known. It was postulated that oxidative conversion of
5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC)
under oxidative stress conditions [166] changes the DNA
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tenance methyltransferase DNMT1 and the methyl-CpG binding
protein 2 (MeCP2) [167,168]. Peroxides can lead via peroxidase-
catalyzed mechanisms in the presence of halogenide ions to che-
mical modiﬁcation of nucleobases such as 5-chlorocytosine, which
mimics 5-mC and can therefore induce inappropriate DNMT1
methylation within CpG sequences [169], thus providing a me-
chanistic link between oxidative stress, inﬂammation and epige-
netic changes. Of note, these chemical DNA modiﬁcations and
associated epigenetic changes are heritable [170]. Impact of ROS
on false epigenetic imprinting is summarized in Fig. 5.Clinical impact
Therapeutic targeting and biomarkers of the classical gene regulation
and DNA repair machinery
Even though major concepts presented in the current review
are describing knowledge gained from fundamental research,
translation into clinic has been achieved in particular with regard
to cancer as the best studied disease related to DNA damage and
epigenetics [150,171]. For example with regard to the DNA repair
machinery, many inhibitory approaches have been taken as an
adjuvant or targeted anti-cancer therapy. A classical example of
targeting the DNA repair machinery is inhibition of poly (ADP-ri-
bose) polymerase 1 (PARP1) [172]. So far, two major concepts
highlighted the clinical usefulness of PARP inhibition as an anti-
neoplasia treatment. The ﬁrst strategy uses a combination therapy
approach, since PARP1 is an essential element of the DNA damage
response (DDR), which cancer cells activate to resist DNA-dama-
ging drugs. Also, as PARP1 is implicated in many DDR processes,
inhibitors of this enzyme are expected to have multiple target
points and will kill cancer cells more effectively [173]. Epigenetic
modiﬁcations are becoming part of an emerging ﬁeld of versatile
biomarkers. For example, ten‐eleven translocation methylcytosine
dioxygenase 2 (TET2) is mutated in more than 15% of all myeloid
malignancies, potentially serving as a disease prognostic factor
[174]. TET enzymes hydroxylate 5-methylcytosine to 5-hydro-
xymethylcytosine, thus being an import enzyme involved in DNA
demethylation. In fact, low levels of 5-hydroxymethylcytosine
have been found in the majority of patients with mutated Tet2. As
of now, there are already 2 medical formulations (decitabine and
azacitidine), approved by the FDA, that are able to remove 5-me-
thylcytosine marks from DNA, leading to its hypomethylated state.
These two drugs have been successfully used in the treatment of
myelodysplastic syndrome and acute myeloid leukemia [175,176].
Considering transcription markers, the estrogen receptor (ER) α is
the most common prognostic marker of breast cancer [36]. Tumors
expressing ER are hormone-dependent and in the majority of
cases will respond to endocrine therapies such as the selective
estrogen receptor antagonist tamoxifen [177] or fulvestrant an
estrogen receptor antagonist which works both by down-reg-
ulating and by degrading the estrogen receptor. Another anti-
cancer therapeutic approach targets the nuclear glutaredoxins
(Grx) and thioredoxins (Trx) reductases. Grx2b and thioredoxin
reductase-1 mRNA levels were signiﬁcantly elevated in patients
with acute myeloid leukemia, suggesting that these enzymes may
represent a promising target for anti-neoplasia treatments [178].
Further, nuclear forms of glutathione transferase (GST) were di-
rectly linked to anti-cancer drug resistance. Accumulation of this
enzyme was observed in cell lines treated with cisplatin, 5-ﬂuor-
ouracil and several other compounds. Inhibition of GST might in-
crease sensitization of the selective cancer lines to the treatment
[179].Therapeutic targeting of the epigenetic gene regulation pathways
Pharmacological targeting of epigenetic pathways is a two-
edged sword. The DNA methyltransferase (DNMT) inhibitor ze-
bularine as well as histone deacetylase (HDAC) inhibitors induce
histone hypomethylation and hyperacetylation, which rescued
SOD2 expression [180], but may also increase CYBB and DUOX1/2
expression [141]. Nevertheless, there are a number of successful
therapeutic interventions at the epigenetic level [150,171] and
most of them are also related to changes in the cellular redox state,
as many of these drugs display indirect antioxidant properties. The
DNMT inhibitor, 5-aza-2′-deoxycytidine, activates Keap1 and Nrf2
resulting in the up-regulation of highly beneﬁcial HO-1 [181].
Further, 5-aza-2′-deoxycytidine prevented hypermethylation of
CpG islands in an enhancer region of intron 2 and in the promoter
region of SOD2 in the setting of pulmonary arterial hypertension
(PAH), a disease with very high mortality [182]. The most relevant
DNMTs are upregulated in PAH (Fig. 5). Normalized SOD2 levels
prevented in PAH animals and patients the development of a
pulmonary artery smooth muscle cell phenotype that was char-
acterized by increased cell proliferation and decreased apoptosis.
This phenotype was mimicked by deletion of SOD using siRNA and
improvement was observed upon treatment of PAH cells with the
SOD mimic MnTBAP, a manganese-porphyrin. Additionally, the 12-
O-tetradecanoylphorbol-13-acetate-inducible expression of extra-
cellular superoxide dismutase (SOD3) was increased by the DNMT
inhibitor 5-azacytidine, whereas SOD3 was suppressed by pre-
treatment with the histone acetyltransferase (HAT) inhibitors,
CPTH2 or garcinol, strongly supporting epigenetic regulation of
this important antioxidant enzyme [183]. These ﬁndings were
reinforced by data from pulmonary arteries, where HDAC inhibi-
tion by trichostatin A increased AcH3K27 and 3meH3K4 marks in
the promoter region of SOD3 which correlated with 10-fold up-
regulation at the protein level [184]. Interestingly, expression of
the NADPH oxidase Nox4 was decreased by 95% by trichostatin A
treatment, suggesting synergistic effects on ROS producing and
detoxifying enzymes. Overall, the epigenetic regulation of SOD3
expression might have an important impact on cancer develop-
ment and tumorigenesis [185] and similar considerations apply for
epigenetic control of SOD2 expression in cancer [180]. The ob-
servation that the term “epigenetic therapy” is often related to
cancer therapy is probably based on the fact that a major part of
research in this area is directed to the epigenetic modulation of
cancer. The natural alkaloid theophylline, a drug previously used
to treat COPD, can induce HDAC2 and can have beneﬁcial effects in
COPD patients at low doses [186,187]. Likewise, the stilbenoid
resveratrol causes changes in gene expression via miRNAs and
epigenetic modiﬁcations [188–190], but also improves the func-
tion of the DNA repair machinery, thereby contributing to genome
stability [191]. The broad effects of natural phytochemical anti-
oxidants on epigenetic pathways are discussed in detail elsewhere
and contribute to the novel disciplines nutrigenetics and nu-
trigenomics [192].
Besides these speciﬁc examples of epigenetically active drugs,
pharmacological drugs with pleiotropic antioxidant effects that are
often based on epigenetic mechanisms have been described (e.g.
statins [193–195]). An interesting candidate is the nitrovasodilator
pentaerithrityl tetranitrate (PETN), the only organic nitrate devoid
of serious side effects such as endothelial dysfunction, nitrate
tolerance and oxidative stress [196]. The molecular explanation for
the beneﬁcial effects of PETN is the induction of heme oxygenase-
1 [197] in an Nrf2-dependent fashion [198]. Likewise, PETN ther-
apy leads to the regulation of more than 1200 genes and up-reg-
ulates several cardio-protective genes [199], but also affects sev-
eral miRNAs. More recently, PETN was shown to induce heritable
epigenetic changes including enhanced AcH3K27 and 3meH3K4
Y. Mikhed et al. / Redox Biology 5 (2015) 275–289 285with subsequent gene activation of endothelial nitric oxide syn-
thase (eNOS), SOD2, glutathione peroxidase-1 (GPx-1) and HO-1
that cause blood pressure reduction in female offspring of PETN-
treated hypertensive rats [200]. Of note, these beneﬁcial effects
were neither shared by other organic nitrates nor by classical NO
donors. Similarly, nitroglycerin-induced nitrate tolerance was im-
proved by in vivo treatment with the HDAC pan-inhibitor tri-
chostatin A (TSA), the speciﬁc HDAC1/3 inhibitor MS-27-275, as
well as the histone acetylase (HAT) activator SPV106, whereas
nitrate tolerance was mimicked by in vivo treatment with the HAT
inhibitor anacardic acid (ANAC) [201]. In summary, these data
support an essential role of histone acetylation in the vasodilatory
properties of nitroglycerin and loss of these properties due to
histone hypoacetylation in the setting of nitrate tolerance.Conclusions
In conclusion, an ever increasing wealth of data indicates that
classical DNA related pathways like gene regulation by transcrip-
tion factors, DNA damage/repair mechanisms, as well as by more
recently acknowledged pathways modulated by epigenetic me-
chanisms, are affected by the redox state of the organism and
subsequently modulate genome stability. We are only starting to
shed light on the intricate signaling cascades and regulatory do-
mains of redox-dependent enzymes that have pronounced effects
on aforementioned genetic and epigenetic systems as well as DNA
damage/repair. An important consequence of current research into
how redox biology is altering the overall genomic and epigenetic
organization, is hopefully the emergence of more sophisticated
and more speciﬁc clinical treatments for disease conditions, in-
cluding chronic inﬂammation/ﬁbrosis, cancer, neurological, meta-
bolic and cardiovascular disorders [202].Conﬂict of interest
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